strategic partners include Arena Pharmaceuticals of USA for the application of
constitutively-activated receptor technology (CART) to selected G protein-
coupled receptors (GPCRs); Chang Geng Memorial Hospital of Taiwan for access
to tumor and hepatitis tissues from 7,000 patients and discovery of novel drug
targets; Fujisawa Pharmaceuticals of Japan for out-licensing of a CART-GPCR
target for discovery of drugs to treat inflammatory diseases; and BioXell of
Italy for collaboration in discovery of novel drug target and therapeutics to
treat chronic inflammation. At present, TaiGen has 88 employees including 76
scientists recruited from the US, Europe, Canada and Taiwan. In addition to
DB67, the company currently has several lead compounds in preclinical
development to treat rheumatoid arthritis, transplant rejection, multiple
sclerosis, cancer and stem cell mobilization.
TTY Biopharm, a public company, is one of the top five pharmaceutical
companies in Taiwan. The company is focusing on oncology, CV, infection and
GI therapeutics. The core strengths of TTY include late stage development
(formulation and clinical studies) as well as brand marketing of new drugs.
TTY aims to be the best strategic partner of international biopharmaceutical
companies for clinical studies and marketing in Asia. In the next five years,
TTY plans to become a leader in anti-cancer drug development and have the most
innovative formulation technology in Asia.
You know Brad is just too exciting too listen to, hear all that excitement in his voice. No wonder partners are far off in the distance. ONCY should spend a few bucks on some P.R. improve their overall image until they have a product, if they ever have one. Likely run out of money first.
Did not hear anything exciting beyond what is already known. Of course could not hear much anyway with the poor sound. I heard partners not enthusastic yet, and maybe not much before 2015. Pre-market dead, no one got very excited.
Do you think their might ever be another press release? Seems Brad has absolutely nothing to say, positive or negative. Makes you wonder what they are thinking about their long investors and the PPS, doesn't it? Do they care, that's the bigger question?
Bet those short sellers, have their shorts in a not right now
ONCY: Traders Watch List: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Riverbed Technology, Inc. (NASDAQ:RVBD), Oncolytics Biotech, Inc. Oren Therapeutics | Jan 14, 2014
ONCY is rated BUY, based on 9 Wall Street analysts' reports. Analysts have an average $6.06 Target Price on ONCY, implying 265.1% Upside to its current price of $1.66.
ONCY: On the Road to Riches in Biotech (12:01AM, Dec 28)